Tirzepatide
$46.20 – $406.56
Tirzepatide vs Retatrutide: Research Comparison
Reference comparison for laboratory researchers. All material on this page is for in-vitro and investigational research only.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Compound class | Dual GIP / GLP-1 agonist | Triple GIP / GLP-1 / glucagon agonist |
| Receptor profile | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Molecular type | Peptide (dual agonist) | Peptide (triple agonist) |
| Development stage | Established in clinical research | Investigational; Phase 3 topline reported, BLA planned Q1 2027 |
Retatrutide
$61.78 – $481.80
Key Differences
- Tirzepatide engages two receptors (GIP, GLP-1); retatrutide adds a third receptor (glucagon) to the profile.
- Retatrutide remains investigational; its receptor-agonist design is the primary distinction discussed in research literature.
Evidence and Limitations
Retatrutide remains investigational. As of October 2026, Lilly has reported positive topline results from multiple Phase 3 trials and announced plans to submit a Biologics License Application to the FDA in Q1 2027.
Regulatory status and development timelines may change; consult official sources (e.g. Eli Lilly releases and ClinicalTrials.gov) for the latest updates. This page does not claim approval, long-term safety, or efficacy.
Last updated: October 2026.
Research Notes
Browse the Metabolic Research category, or view batch documentation for Tirzepatide and Retatrutide. All AminoForge material is supplied as a lyophilized research vial with an independently HPLC-verified batch record, for laboratory research use only.